The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders

• Main Authors: Philippine Aupy, Lucía Echevarría, Karima Relizani, Aurélie Goyenvalle
• Format: Article
• Language: English
• Published: MDPI AG 2017-12-01
• Series: Biomedicines
• Subjects: antisense oligonucleotides; tricyclo-DNA; gapmers; splice-switching; exon-skipping; exon-re-inclusion; delivery
• Online Access: https://www.mdpi.com/2227-9059/6/1/2

Antisense Oligonucleotides (ASOs) represent very attractive therapeutic compounds for the treatment of numerous diseases. The antisense field has remarkably progressed over the last few years with the approval of the first antisense drugs and with promising developments of more potent and nuclease resistant chemistries. Despite these recent clinical successes and advances in chemistry and design, effective delivery of ASOs to their target tissues remains a major issue. This review will describe the latest advances obtained with the tricyclo-DNA (tcDNA) chemistry which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration. We will examine the variety of therapeutic approaches using both fully modified tcDNA-ASOs and gapmers, including splice switching applications, correction of aberrant splicing, steric blocking strategies and targeted gene knock-down mediated by RNase H recruitment. We will then discuss the merits and potential liabilities of the tcDNA chemistry in the context of ASO drug development.